Trial Profile
A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Breast cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer
- Focus Therapeutic Use
- 09 May 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 09 May 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 26 Mar 2018 New trial record